TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23426033

Group type: EXPERIMENTAL
Intervention: DHA supplementation (600 mg/d)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 21768541

Group type: COMPARATOR
Intervention: Soy protein supplementation (40 g/d for 8 weeks)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Milk protein supplementation (40 g/d for 8 weeks)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (control)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Soy protein vs Milk protein
Number of subjects: 352
Study: 19961750

Group type: EXPERIMENTAL
Intervention: Mini-screw implants
Number of subjects: 42

Group type: COMPARATOR
Intervention: Transpalatal arch (TPA)
Number of subjects: 42
Study: 17027360

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Number of subjects: 38
Study: 14605283

Group type: EXPERIMENTAL
Intervention: Super-flux dialysis
Number of subjects: 45

Group type: COMPARATOR
Intervention: High-flux dialysis
Number of subjects: 45

Group type: COMPARATOR
Intervention: Low-flux dialysis
Number of subjects: 45
Study: 10741813

Group type: EXPERIMENTAL
Intervention: Bupivacaine (5 ml of 0.25% bupivacaine at each incisional area, total of 20 ml)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (physiologic saline solution, total of 20 ml)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study: 9373821

Group type: EXPERIMENTAL
Intervention: Opportunistic health screening tool
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 1586367

Group type: EXPERIMENTAL
Intervention: Behavioural therapy (exposure in vivo and response prevention)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Behavioural therapy followed by cognitive therapy
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cognitive therapy followed by behavioural therapy
Number of subjects: 6
Study: 3515932

Group type: EXPERIMENTAL
Intervention: Moricizine (Ethmozine)
Number of subjects: 17
Study: 31292531

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1150
Study: 30439322

Group type: EXPERIMENTAL
Intervention: Xuebijing injection
Number of subjects: 189

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 189
Study: 27213491

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Higher consistency in session attendance
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Longer time interval between Sessions 4 and 5
Number of subjects: 136
Study: 24338242

Group type: EXPERIMENTAL
Intervention: Capnographic monitoring
Number of subjects: 533

Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Anesthesiologist-administered sedation
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Nurse-administered propofol sedation (NAPS) or endoscopist-directed sedation (EDS)
Number of subjects: 533
Study: 23240152

Group type: EXPERIMENTAL
Intervention: Melatonin (melaxen, 1.5 mg, 2 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20479445

Group type: EXPERIMENTAL
Intervention: Dynamic splinting for nightly wear to obtain a low-load, prolonged-duration stretch with dynamic tension
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (received nonsteroidal anti-inflammatory drugs, orthoses, and corticosteroid injections if needed)
Number of subjects: 60
Study: 18690305

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg bid)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 15230045

Group type: EXPERIMENTAL
Intervention: Trimetazidine 60 mg/day for 4 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 47
Study: 11382726

Group type: EXPERIMENTAL
Intervention: GP IIb/IIIa antagonist therapy with >/=95% platelet inhibition at 10 minutes after therapy initiation
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Platelet function inhibition <70% at 8 hours after therapy initiation
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Platelet function inhibition >/=95% at 10 minutes after therapy initiation
Number of subjects: 500
Study: 9404700

Group type: EXPERIMENTAL
Intervention: High STn expression (defined as >25% cells immunoreactive)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: High STn expression
Number of subjects: 207

Group type: COMPARATOR
Intervention: Low STn expression
Number of subjects: 207
Study: 8102894

Group type: COMPARATOR
Intervention: Cefotaxime (Claforan) 2 g intravenously at induction and 3 and 9 hours later (n = 280)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Cefotaxime 2 g plus metronidazole (Flagyl) 1.5 g intravenously at induction (n = 287)
Number of subjects: 567
Study: 3111953

Group type: EXPERIMENTAL
Intervention: Antithrombin III (AT III) concentrate
Number of subjects: 39

Group type: COMPARATOR
Intervention: FOY (injectable synthetic protease inhibitor)
Number of subjects: 39
Study: 29884217

Group type: EXPERIMENTAL
Intervention: Stratified care based on STarT Back Tool classification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current practice (physiotherapists blinded to STarT score)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stratified care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current practice
Number of subjects: 0
Study: 26941098

Group type: EXPERIMENTAL
Intervention: ICSI using ZP-bound sperm
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard ICSI
Number of subjects: 84
Study: 25239512

Group type: EXPERIMENTAL
Intervention: Mini-trampoline (MT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Aquatic gymnastics (AG)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: General floor gymnastics (GG)
Number of subjects: 74
Study: 23644995

Group type: EXPERIMENTAL
Intervention: Targeting lower arterial oxygen saturations (85% to 89%)
Number of subjects: 1201

Group type: COMPARATOR
Intervention: Targeting higher arterial oxygen saturations (91% to 95%)
Number of subjects: 1201
Study: 20821817

Group type: EXPERIMENTAL
Intervention: Acupuncture (AG)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham Acupuncture (SG)
Number of subjects: 35
Study: 18467725

Group type: EXPERIMENTAL
Intervention: Initial adjuvant treatment with fluorouracil (FU)-based therapy
Number of subjects: 17381

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 17381

Group type: EXPERIMENTAL
Intervention: Initial stage II disease
Number of subjects: 17381

Group type: EXPERIMENTAL
Intervention: Patients entered more recently onto trials (1986 to 1999)
Number of subjects: 17381
Study: 16642886

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 12556006

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 mcg twice daily
Number of subjects: 456

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456
Study: 10987161

Group type: EXPERIMENTAL
Intervention: Unna semirigid dressings (SRD)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Elastic bandage soft dressings (ED)
Number of subjects: 21
Study: 8978020

Group type: EXPERIMENTAL
Intervention: Live varicella zoster virus (VZV) vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Killed varicella zoster virus (VZV) vaccine
Number of subjects: 0
Study: 1462639

Group type: EXPERIMENTAL
Intervention: Microcrystalline collagen powder (CL)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Fibrin glue (FG)
Number of subjects: 62
Study: 6152344

Group type: EXPERIMENTAL
Intervention: Cholecystokinin-octapeptide (CCK-8) 10 micrograms weekly intravenous injections
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 18
Study: 30719442

Group type: EXPERIMENTAL
Intervention: Amplatz group (AG)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Balloon group (BG)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study: 30385540

Group type: COMPARATOR
Intervention: No saline
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: 0.225% saline
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 427
Study: 26541531

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham-CPAP (placebo-controlled)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Baseline (before treatment)
Number of subjects: 72
Study: 24809397

Group type: EXPERIMENTAL
Intervention: Mindfulness-based psychoeducation
Number of subjects: 107

Group type: COMPARATOR
Intervention: Conventional psychoeducation
Number of subjects: 107

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 107
Study: 22366477

Group type: EXPERIMENTAL
Intervention: HIV/STI risk reduction intervention (n = 49)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: HIV/STI risk reduction and motivational interviewing (n = 58)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Wellness promotion (control group, n = 59)
Number of subjects: 166
Study: 21137167

Group type: EXPERIMENTAL
Intervention: Immunotherapy with Urovaxom and Luivac combined with small doses of fluorochinolones over 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-term chemoprophylaxis with small doses of fluorochinolones
Number of subjects: 0
Study: 17938729

Group type: EXPERIMENTAL
Intervention: Vitamin E and selenium supplementation
Number of subjects: 115
Study: 15226323

Group type: EXPERIMENTAL
Intervention: Bicalutamide (150 mg by mouth daily)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 52
Study: 11420821

Group type: EXPERIMENTAL
Intervention: No-suction group (n = 154)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Control group with wound drainage (n = 151)
Number of subjects: 305
Study: 10193282

Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 20
Study: 7886332

Group type: EXPERIMENTAL
Intervention: Intervention group (12-week program added to ordinary daycare agenda)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (ordinary daycare agenda)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intervention group (12-week program)
Number of subjects: 65
Study: 3264710

Group type: EXPERIMENTAL
Intervention: Aspirin (600 mg four times daily; 17 doses)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indomethacin BP (50 mg three times daily; 13 doses)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indocid‐R (75 mg twice daily; 9 doses)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indomethacin Continus (75 mg twice daily; 9 doses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31074089

Group type: EXPERIMENTAL
Intervention: Nanocurcumin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29908436

Group type: COMPARATOR
Intervention: Exposure to zero ACEs
Number of subjects: 1469

Group type: COMPARATOR
Intervention: Exposure to one ACE
Number of subjects: 1469

Group type: COMPARATOR
Intervention: Exposure to two ACEs
Number of subjects: 1469

Group type: COMPARATOR
Intervention: Exposure to three or more ACEs
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: ACEs exposure
Number of subjects: 1469
Study: 26515258

Group type: EXPERIMENTAL
Intervention: Individually tailored cutpoint based on an equation combining age, age(2), and 400 m gait speed
Number of subjects: 1448

Group type: COMPARATOR
Intervention: Standard fixed cutpoints
Number of subjects: 1448
Study: 25341154

Group type: EXPERIMENTAL
Intervention: RFA of both viable HCC and retained iodized oil (group A)
Number of subjects: 85

Group type: COMPARATOR
Intervention: RFA of viable HCC only (group B)
Number of subjects: 85
Study: 23514770

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (MMS) with 5 mg of iron (ferrous sulfate) for 5 months
Number of subjects: 2730

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2730
Study: 20470276

Group type: EXPERIMENTAL
Intervention: Iron sucrose (50 mg) with N-acetylcysteine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Iron sucrose (100 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Iron sucrose (50 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Haemodialysis
Number of subjects: 40
Study: 18627279

Group type: EXPERIMENTAL
Intervention: mDOT intervention
Number of subjects: 50
Study: 16934143

Group type: EXPERIMENTAL
Intervention: Back care education session followed by the 12-week USC Spine Exercise Program
Number of subjects: 100

Group type: COMPARATOR
Intervention: One session of back care education
Number of subjects: 100
Study: 14736075

Group type: EXPERIMENTAL
Intervention: Inosiplex (Isoprinosine) 100 mg/kg/day to a maximum of 3 g/day, taken orally in three divided doses for 6 months
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Combined treatment of inosiplex and intraventricular interferon‐alpha2b (Intron A), starting with 100,000 U/m2 and escalating to 1,000,000 U/m2 over 5 inpatient days, then 1,000,000 U/m2 twice a week for 6 months
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 121
Study: 14743227

Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin
Number of subjects: 10305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10305
Study: 10425809

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (25 mg/kg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 56
Study: 7593739

Group type: EXPERIMENTAL
Intervention: Height (continuous)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Height (continuous) in males
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Height (continuous) in females
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Height (continuous) in untreated males (not randomized to propranolol)
Number of subjects: 0
Study: 2272191

Group type: EXPERIMENTAL
Intervention: Cronassial (100 mg in 2 ml buffered solution)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 6250769

Group type: EXPERIMENTAL
Intervention: Topical administration of Acyclovir (9‐(2‐hydroxyethoxymethyl)guanine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 22655911

Group type: EXPERIMENTAL
Intervention: SRP + 0.5% AZM
Number of subjects: 63

Group type: COMPARATOR
Intervention: SRP + placebo gel
Number of subjects: 63
Study: 25575254

Group type: EXPERIMENTAL
Intervention: Large-pore polypropylene mesh
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control (no mesh)
Number of subjects: 107
Study: 24075453

Group type: EXPERIMENTAL
Intervention: Canakinumab 5 mg
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Canakinumab 15 mg
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Canakinumab 50 mg
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study: 21860339

Group type: EXPERIMENTAL
Intervention: Nevirapine treatment in patients with different genotypes
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Nevirapine treatment in patients with CYP2B6 516G>T polymorphism
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Nevirapine treatment in patients with CYP2C19 8403AA genotype
Number of subjects: 271
Study: 19387646

Group type: EXPERIMENTAL
Intervention: Methotrexate plus TNF alpha antagonist
Number of subjects: 144

Group type: COMPARATOR
Intervention: Methotrexate (15–20 mg weekly for 3 months)
Number of subjects: 144
Study: 17426399

Group type: EXPERIMENTAL
Intervention: Xylitol gum (XYL)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Maltitol gum (MAL)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (CR)
Number of subjects: 127
Study: 15480990

Group type: EXPERIMENTAL
Intervention: Recombinant coagulation factor VIIa (rFVIIa) 100 microg/kg, 8 doses
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 11561267

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with local anesthetics (group B)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Systemic buprenorphine (group A)
Number of subjects: 2
Study: 9645802

Group type: EXPERIMENTAL
Intervention: Neoral (cyclosporine microemulsion)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Sandimmune (traditional cyclosporine)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 466

Group type: COMPARATOR
Intervention: Sandimmune
Number of subjects: 466
Study: 7935146

Group type: EXPERIMENTAL
Intervention: Occupational exposure to mercury
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no exposure to mercury)
Number of subjects: 91
Study: 3356847

Group type: EXPERIMENTAL
Intervention: Four different SR theophylline formulations
Number of subjects: 10
Study: 30770279

Group type: EXPERIMENTAL
Intervention: Cone-beam computed tomographic (CBCT) imaging
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PR, CBCT imaging, and 3D Endo software
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional radiographs (PR) only
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PR and CBCT imaging
Number of subjects: 60
Study: 28954098

Group type: EXPERIMENTAL
Intervention: Homologous platelet gel
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hydrocolloid dressing
Number of subjects: 16
Study: 25902745

Group type: EXPERIMENTAL
Intervention: J-tip guidewire
Number of subjects: 131

Group type: COMPARATOR
Intervention: Angled-tip guidewire
Number of subjects: 131
Study: 23646835

Group type: EXPERIMENTAL
Intervention: Mortality reminders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control topic
Number of subjects: 0
Study: 21333984

Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone
Number of subjects: 1373

Group type: COMPARATOR
Intervention: Micronized vaginal P gel
Number of subjects: 1373

Group type: COMPARATOR
Intervention: Micronized P capsule
Number of subjects: 1373
Study: 19250079

Group type: EXPERIMENTAL
Intervention: CRT-PM
Number of subjects: 233

Group type: COMPARATOR
Intervention: CRT-D
Number of subjects: 233
Study: 17499653

Group type: EXPERIMENTAL
Intervention: Topical lidocaine and epinephrine (TLE) using sequential layered application
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2% lidocaine infiltration anesthesia (Control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Topical lidocaine and epinephrine (TLE)
Number of subjects: 100
Study: 15201857

Group type: EXPERIMENTAL
Intervention: Infasurf
Number of subjects: 40

Group type: COMPARATOR
Intervention: Survanta
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both Infasurf and Survanta
Number of subjects: 40
Study: 12585303

Group type: EXPERIMENTAL
Intervention: Pharmaceutical pricing after the policy change regarding patient out-of-pocket expenses.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Branded products facing generic competitors.
Number of subjects: 0
Study: 9706049

Group type: EXPERIMENTAL
Intervention: Guar gum-based diltiazem formulations
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dilacor XR
Number of subjects: 8
Study: 7699350

Group type: EXPERIMENTAL
Intervention: Environmental patient education materials (office-based videos, pamphlets, and posters)
Number of subjects: 770

Group type: COMPARATOR
Intervention: Control group (no educational materials)
Number of subjects: 770
Study: 2712549

Group type: EXPERIMENTAL
Intervention: 100 mg/day amantadine
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: 200 mg/day amantadine
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: 50 mg/day amantadine
Number of subjects: 554

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study: 325650

Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 to 10 milligrams)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 19
Study: 31874181

Group type: EXPERIMENTAL
Intervention: Sleep restriction (5 hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sleep fragmentation (light on every hour)
Number of subjects: 20
Study: 31225666

Group type: EXPERIMENTAL
Intervention: OPTIONS (decision support intervention)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 37
Study: 29188864

Group type: EXPERIMENTAL
Intervention: Higher protein intake (1.3 g/kg/day)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Lower protein intake (0.8 g/kg/day)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Testosterone (vs. placebo)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (vs. testosterone)
Number of subjects: 92
Study: 25967892

Group type: EXPERIMENTAL
Intervention: Enhanced nutrient supply (increased energy, protein, fat, essential fatty acids, and vitamin A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard nutritional care (control group)
Number of subjects: 50
Study: 23488545

Group type: EXPERIMENTAL
Intervention: Histamine (30 nmol min(‐1))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: H1-receptor antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0
Study: 22123796

Group type: EXPERIMENTAL
Intervention: Nicotine therapy sampling
Number of subjects: 849

Group type: COMPARATOR
Intervention: PQA intervention
Number of subjects: 849
Study: 19619700

Group type: EXPERIMENTAL
Intervention: Baseline use of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB)
Number of subjects: 16588

Group type: EXPERIMENTAL
Intervention: Patients with early VF/VT on baseline ACEI/ARB
Number of subjects: 16588

Group type: COMPARATOR
Intervention: Patients without early VF/VT
Number of subjects: 16588

Group type: EXPERIMENTAL
Intervention: Patients with early VF/VT
Number of subjects: 16588
Study: 16969070

Group type: EXPERIMENTAL
Intervention: sorafenib (BAY 43-9006)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0